Literature DB >> 1313846

Identification and molecular cloning of tactile. A novel human T cell activation antigen that is a member of the Ig gene superfamily.

P L Wang1, S O'Farrell, C Clayberger, A M Krensky.   

Abstract

We have identified and cloned cDNA for a novel cell-surface protein that we have named Tactile for T cell activation, increased late expression. It is expressed on normal T cell lines and clones, and some transformed T cells, but no other cultured cell lines tested. It is expressed at low levels on peripheral T cells and is strongly up-regulated after activation, peaking 6 to 9 days after the activating stimulus. It is also up-regulated on NK cells activated in allogeneic cultures. It is not found on peripheral B cells but is expressed at very low levels on activated B cells. Tactile-specific mAb immunoprecipitates a band of 160 kDa when reduced and bands of 240, 180, and 160 kDa nonreduced. Using an antiserum produced with affinity-purified Tactile protein to screen a lambda gt11 library, we have identified Tactile cDNA. Northern blot analysis shows an expression pattern similar to that of the protein and transfection of COS cells with the full-length 5.2-kb cDNA results in cell-surface expression. Comparison with the sequence databanks show that Tactile is a member of the immunoglobulin gene superfamily, with similarity to Drosophila amalgam, the melanoma Ag MUC-18, members of the carcinoembryonic Ag family, the poliovirus receptor, and the neural cell adhesion molecule. The deduced primary sequence encodes a protein with three Ig domains, a long serine/threonine/proline-rich region typical of an extensively O-glycosylated domain, a transmembrane domain, and a 45 residue cytoplasmic domain. These data suggest that Tactile may be involved in adhesive interactions of activated T and NK cells during the late phase of the immune response.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1313846

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  43 in total

1.  Investigating cell surface markers on normal hematopoietic stem cells in three different niche conditions.

Authors:  Swati Garg; Manisha Madkaikar; Kanjaksha Ghosh
Journal:  Int J Stem Cells       Date:  2013-11       Impact factor: 2.500

2.  The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions.

Authors:  Christopher J Chan; Ludovic Martinet; Susan Gilfillan; Fernando Souza-Fonseca-Guimaraes; Melvyn T Chow; Liam Town; David S Ritchie; Marco Colonna; Daniel M Andrews; Mark J Smyth
Journal:  Nat Immunol       Date:  2014-03-23       Impact factor: 25.606

Review 3.  A novel interface consisting of homologous immunoglobulin superfamily members with multiple functions.

Authors:  Zhuwei Xu; Boquan Jin
Journal:  Cell Mol Immunol       Date:  2010-01       Impact factor: 11.530

4.  CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia.

Authors:  Naoki Hosen; Christopher Y Park; Naoya Tatsumi; Yusuke Oji; Haruo Sugiyama; Martin Gramatzki; Alan M Krensky; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-18       Impact factor: 11.205

5.  Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome.

Authors:  Véronique M Braud; Jérôme Biton; Etienne Becht; Samantha Knockaert; Audrey Mansuet-Lupo; Estelle Cosson; Diane Damotte; Marco Alifano; Pierre Validire; Fabienne Anjuère; Isabelle Cremer; Nicolas Girard; Dominique Gossot; Agathe Seguin-Givelet; Marie-Caroline Dieu-Nosjean; Claire Germain
Journal:  Oncoimmunology       Date:  2018-01-29       Impact factor: 8.110

6.  CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity.

Authors:  Amelia Roman Aguilera; Viviana P Lutzky; Deepak Mittal; Xian-Yang Li; Kimberley Stannard; Kazuyoshi Takeda; Günter Bernhardt; Michele W L Teng; William C Dougall; Mark J Smyth
Journal:  Oncoimmunology       Date:  2018-02-01       Impact factor: 8.110

Review 7.  Targeting PVR (CD155) and its receptors in anti-tumor therapy.

Authors:  Paola Kučan Brlić; Tihana Lenac Roviš; Guy Cinamon; Pini Tsukerman; Ofer Mandelboim; Stipan Jonjić
Journal:  Cell Mol Immunol       Date:  2018-10-01       Impact factor: 11.530

Review 8.  TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells.

Authors:  Yoshikane Kikushige; Toshihiro Miyamoto
Journal:  Int J Hematol       Date:  2013-09-18       Impact factor: 2.490

9.  Dynamic interplay of transcriptional machinery and chromatin regulates "late" expression of the chemokine RANTES in T lymphocytes.

Authors:  Yong-Tae Ahn; Boli Huang; Lisa McPherson; Carol Clayberger; Alan M Krensky
Journal:  Mol Cell Biol       Date:  2006-10-30       Impact factor: 4.272

10.  Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis.

Authors:  Heidi Harjunpää; Stephen J Blake; Elizabeth Ahern; Stacey Allen; Jing Liu; Juming Yan; Viviana Lutzky; Kazuyoshi Takeda; Amy Roman Aguilera; Camille Guillerey; Deepak Mittal; Xian Yang Li; William C Dougall; Mark J Smyth; Michele W L Teng
Journal:  Oncoimmunology       Date:  2018-03-26       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.